PRI-101 inhibited aggregation of α-synuclein and actively disassembled fibrils throughout in vitro and in vivo fashions related to Parkinson’s illness
Dusseldorf, Germany, March 19, 2026 – Priavoid GmbH (“Priavoid”) at the moment introduced preclinical proof-of-concept information for PRI-101, its orally out there all-d-peptide candidate being developed for the remedy of Parkinson’s illness (PD) and associated synucleinopathies. The info might be offered in a poster session by Dr. Marc Sevenich on the Worldwide Convention on Alzheimer’s and Parkinson’s Ailments and Associated Neurological Problems (AD/PDTM 2026) in Copenhagen, Denmark.
PRI-101 was developed utilizing Priavoid’s proprietary detangler platform and is designed to focus on and disassemble α-synuclein (α-syn) aggregates, which play a key function within the illness pathology and within the induction of toxicity that results in neurodegeneration in PD, a number of system atrophy (MSA), and different synucleinopathies. PRI-101 is binding to the α-syn subunit inside poisonous and self-replicating neurodegenerative aggregates and selling their conversion again in the direction of native, non-toxic varieties, with the goal of counteracting disease-driving aggregation processes.
“Parkinson’s disease affects more than 6 million people worldwide and remains an area of profound unmet medical need, with patients still lacking therapies that meaningfully alter the course of disease,” stated Dr. Antje Willuweit, Director Preclinical Improvement at Priavoid GmbH. “Taken together, these preclinical data suggest that PRI-101 has the potential to be a first-in-class therapeutic candidate with disease-modifying potential for Parkinson’s disease and other related synucleinopathies. We look forward to advancing this candidate towards the clinic to address a substantial need for new disease-modifying therapeutic options.”
Preclinical information offered on the convention demonstrated that PRI-101 can immediately goal and cut back pathological α-syn aggregates throughout a number of Parkinson’s illness fashions. In vitro research confirmed that PRI-101 disassembled α-syn preformed fibrils (PFFs) and deactivated their seeding exercise in a concentration- and time-dependent method. It additionally demonstrated ex vivo goal engagement, lowering α-syn combination ranges in postmortem mind samples from sufferers with PD, MSA, and dementia with Lewy our bodies. Pharmacokinetic research following single and a number of doses confirmed that PRI-101 effectively crosses the blood mind barrier and achieves significant penetration into the mind. In a human mind organoid mannequin system for synucleinopathies and two distinct PD mouse fashions, PRI-101 lowered α-syn aggregates and ranges of phosphorylated α-syn, a marker of α-syn aggregation. In vivo, PRI-101 was related to extended median survival versus placebo. Quick- and long-term remedy additionally led to a dose-dependent discount of α-syn aggregates within the mind (together with within the substantia nigra), accompanied by important enhancements in behavioral efficiency.
More Read
This work is funded by a grant from The Michael J. Fox Basis for Parkinson’s Analysis.
About PriavoidPriavoid’s novel class of orally out there all-d-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative issues. We goal to ascertain scientific proof-of-concept via our lead program, PRI-002, which can full a Section 2 trial in Alzheimer’s illness in 2026. Priavoid has constructed a centered pipeline of detangler compounds which are non-immunogenic and attain their oligomer targets within the mind and contained in the affected cells. Our purpose is to develop disease-modifying therapies that deal with the underlying biology of neurodegeneration and drive significant scientific profit for sufferers.
Contacts:
